J. Ling
Southwest Research Institute,
United States
Keywords: biomanufacturing, bioreactor, cell and gene therapy
Summary:
To address the growing demand of personalized medicine and rapid therapeutic deployment, we are developing a portable, versatile, and automated (PVA) biomanufacturing platform. Built on a proprietary 3D-printed bioreactor technology developed at the Southwest Research Institute (SwRI), this platform is expected to replace manually operated 2D culture devices, and overcome the limitations of existing automated bioreactor systems, enabling a more efficient, scalable, and standardized approach to CGT manufacturing. This platform is designed for cost-effective, point-of-care manufacturing of cell and gene therapy (CGT) products, replacing centralized production with on-demand, patient-specific treatment. This approach improves patient outcomes, reduces healthcare costs, enhances quality, and increases accessibility for a broader population. Its versatility supports a wide range of CGTs, while its compact, portable design facilitates deployment in diverse settings, from urban hospitals to remote clinics.